Last 23 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -8.18 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 12.36 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 29.73 | 5.90 | 3.50 | 7.06 | 20.50 | 11.85 | 15.26 | 8.58 | 25.95 | 12.49 | 35.92 | 32.04 | 23.67 | 18.01 | 5.39 | 2.39 | 42.39 | 40.19 | 30.07 | 18.79 | 44.63 |
| — | -50.2% | -77.1% | -17.8% | -21.0% | -5.2% | -57.5% | -73.2% | +9.7% | -30.6% | +566.1% | +1242.7% | -44.2% | -55.2% | -82.1% | -87.3% | -5.0% | — | — | — | — | |
| P/B Ratio | 1.98 | 1.22 | 0.77 | 0.89 | 0.66 | 0.70 | 0.93 | 1.29 | 1.48 | 1.29 | 1.81 | 1.96 | 1.60 | 1.50 | 1.07 | 0.99 | 5.25 | 5.10 | 5.18 | 4.90 | 4.91 |
| — | +72.7% | -17.2% | -31.4% | -55.4% | -45.5% | -48.8% | -34.3% | -7.1% | -13.7% | +69.2% | +98.8% | -69.6% | -70.6% | -79.3% | -79.8% | +6.8% | — | — | — | — | |
| P/FCF | — | 30.83 | — | — | — | — | — | — | — | — | — | — | — | — | 3.32 | — | — | — | 37.61 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -91.2% | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 6.75 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 8.55 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -18.2% | 95.5% | 58.3% | 7.9% | -109.2% | 93.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 11.6% | 30.0% | 74.2% | 90.7% | 34.8% | 37.6% | 58.4% | 78.9% | 100.0% |
| — | +2.3% | -41.7% | -92.1% | -209.2% | -6.7% | 0.0% | 0.0% | +765.2% | +233.0% | +34.8% | +10.2% | -66.8% | -20.2% | +27.1% | +15.0% | -65.2% | -62.4% | -41.6% | -21.1% | — | |
| Operating Margin | -383.1% | -49.5% | -54.9% | -186.7% | -811.3% | -416.2% | -453.6% | -147.0% | -473.7% | -214.1% | -593.3% | -439.8% | -370.6% | -277.9% | -49.7% | 25.3% | -218.8% | -172.3% | -90.1% | -21.7% | -156.2% |
| — | +88.1% | +87.9% | -27.1% | -71.2% | -94.4% | +23.5% | +66.6% | -27.8% | +22.9% | -1094.5% | -1837.9% | -69.4% | -61.3% | +44.8% | +216.6% | -40.0% | +9.6% | +42.7% | -20.8% | — | |
| Net Margin | -347.0% | -43.7% | -53.5% | -169.3% | -738.1% | -407.4% | -438.1% | -121.0% | -392.4% | -179.0% | -498.8% | -291.4% | -287.3% | -212.0% | -36.1% | 19.3% | -182.3% | -142.7% | -65.3% | -20.1% | -125.7% |
| — | +89.3% | +87.8% | -40.0% | -88.1% | -127.5% | +12.2% | +58.5% | -36.6% | +15.6% | -1283.6% | -1610.4% | -57.6% | -48.5% | +44.8% | +196.0% | -45.0% | +7.6% | +46.4% | -1585.2% | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -23.4% | -2.2% | -2.9% | -5.2% | -6.1% | -5.9% | -6.5% | -4.5% | -5.6% | -4.6% | -6.2% | -4.4% | -4.8% | -4.4% | -1.8% | 2.4% | -5.6% | -4.6% | -2.7% | -1.3% | -6.9% |
| — | +62.2% | +55.2% | -15.5% | -9.6% | -29.5% | -5.4% | -2.6% | -16.9% | -4.8% | -244.2% | -282.1% | +14.5% | +4.3% | +34.9% | +281.8% | +19.1% | +100.0% | +59.8% | -1868.7% | — | |
| ROA | -20.7% | -2.0% | -2.6% | -4.6% | -5.5% | -5.3% | -5.8% | -4.0% | -4.9% | -4.0% | -5.2% | -3.7% | -3.9% | -3.6% | -1.5% | 2.1% | -4.6% | -3.8% | -2.3% | -1.0% | -5.6% |
| — | +62.0% | +55.0% | -16.8% | -11.5% | -33.5% | -10.6% | -8.5% | -24.0% | -9.8% | -256.3% | -277.0% | +14.7% | +4.8% | +37.0% | +298.1% | +16.7% | +99.8% | +57.3% | -1842.6% | — | |
| ROIC | -19.7% | -2.0% | -2.3% | -4.4% | -5.1% | -4.4% | -5.0% | -4.2% | -5.1% | -4.0% | -5.4% | -4.9% | -4.6% | -4.2% | -1.9% | 2.4% | -4.7% | -3.8% | -2.7% | -1.0% | -6.2% |
| — | +55.7% | +53.7% | -5.9% | -0.6% | -9.3% | +7.2% | +14.4% | -11.1% | +4.6% | -188.1% | -302.5% | +4.1% | -10.5% | +31.3% | +334.8% | +23.2% | +99.9% | +58.5% | -35.7% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.00 | 0.12 | 0.04 | 0.06 | 0.04 |
| — | -12.6% | -8.9% | -5.4% | -7.1% | +0.5% | -0.7% | -0.9% | +1.3% | +4.1% | +9.0% | +7.5% | +2301.8% | -32.3% | +98.2% | +27.8% | -92.0% | -99.0% | -98.8% | +437.1% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.11 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.02 | 4.80 | 4.80 | 4.02 | 5.00 | 3.77 | 4.70 | 4.52 | 4.62 | 4.75 | 4.38 | 4.11 | 4.26 | 4.78 | 5.59 | 4.80 | 0.04 | 0.55 | 0.20 | 1.10 | 0.40 |
| — | +27.3% | +2.2% | -11.0% | +8.0% | -20.8% | +7.3% | +10.0% | +8.5% | -0.6% | -21.6% | -14.5% | +10227.9% | +766.5% | +2677.3% | +338.3% | -89.7% | +844.3% | — | -6.1% | — | |
| Quick Ratio | 4.02 | 4.80 | 4.80 | 4.02 | 4.96 | 3.77 | 4.70 | 4.52 | 4.62 | 4.75 | 4.38 | 4.11 | 4.26 | 4.78 | 5.59 | 4.80 | 0.04 | 0.55 | 0.20 | 1.10 | 0.40 |
| — | +27.3% | +2.2% | -11.0% | +7.3% | -20.8% | +7.3% | +10.0% | +8.5% | -0.6% | -21.6% | -14.5% | +10227.9% | +766.5% | +2677.3% | +338.3% | -89.7% | +844.3% | — | -6.1% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -3807.00 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OABI stock.
OmniAb, Inc.'s current P/E is -8.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
OmniAb, Inc.'s current operating margin is -383.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking OmniAb, Inc.'s business trajectory between earnings reports.